Compare Incyte Corporation (INCY) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Paychex, Inc. — how do they compare? Incyte Corporation trades at $121.04 (market cap $24.54B), while Paychex, Inc. trades at $119.73 (market cap $43.14B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays a 3.92% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PAYX | |
|---|---|---|
Market Cap | $24.54B | $43.14B |
Sector | Health | Industrials |
52-Week High | $129.93 | $140.81 |
52-Week Low | $81.61 | $85.57 |
Enterprise Value | $20.04B | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Paychex (PAYX) trades at $119.93, down 1.03% today, with a bullish technical outlook and strong profitability. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.33. The company maintains robust margins, including a 27.03% net income margin, and pays a steady dividend of $1.19 quarterly. Cash flow trends indicate operational strength, though 2025 saw significant investing outflows.
The stock presents a mixed outlook: solid fundamentals and dividend appeal are offset by a consensus 'Hold' rating and a price target below the current level. Risks include high valuation multiples and potential economic sensitivity for small business clients. Upside depends on sustained earnings growth and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
